Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | NEJM
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition…